Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

TWYNSTA

AMLODIPINE BESYLATE; TELMISARTAN

Standard Dose
EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TWYNSTA is listed in Drugs@FDA under application 022401 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient AMLODIPINE BESYLATE; TELMISARTAN Form and strength TABLET;ORAL - EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2018-02-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview TWYNSTA is listed in Drugs@FDA under application 022401 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMLODIPINE BESYLATE; TELMISARTAN Form and strength TABLET;ORAL - EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2018-02-01 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.